ALS: edaravone found safe, effective in well-defined group

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Edaravone (Radicava) slowed the decline in function during 24 wk in patients with early-stage definite or probable amyotrophic lateral sclerosis (ALS).

Why this matters

  • ALS is incurable and has limited treatment options.

Key results

  • Patients in the edaravone group had ...